Integrated Wealth Concepts LLC Buys 844 Shares of West Pharmaceutical Services, Inc. $WST

Integrated Wealth Concepts LLC raised its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 34.5% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,287 shares of the medical instruments supplier’s stock after acquiring an additional 844 shares during the quarter. Integrated Wealth Concepts LLC’s holdings in West Pharmaceutical Services were worth $736,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Zions Bancorporation National Association UT acquired a new stake in shares of West Pharmaceutical Services during the first quarter worth approximately $25,000. Quarry LP acquired a new stake in shares of West Pharmaceutical Services during the first quarter worth approximately $27,000. First Horizon Advisors Inc. increased its holdings in shares of West Pharmaceutical Services by 85.0% during the first quarter. First Horizon Advisors Inc. now owns 185 shares of the medical instruments supplier’s stock worth $41,000 after buying an additional 85 shares in the last quarter. Opal Wealth Advisors LLC acquired a new stake in shares of West Pharmaceutical Services during the first quarter worth approximately $53,000. Finally, Whipplewood Advisors LLC increased its holdings in shares of West Pharmaceutical Services by 248.0% during the first quarter. Whipplewood Advisors LLC now owns 261 shares of the medical instruments supplier’s stock worth $58,000 after buying an additional 186 shares in the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Price Performance

WST opened at $253.50 on Friday. The company has a fifty day moving average price of $241.04 and a two-hundred day moving average price of $225.38. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.08 and a current ratio of 2.78. West Pharmaceutical Services, Inc. has a 52 week low of $187.43 and a 52 week high of $352.33. The firm has a market capitalization of $18.23 billion, a PE ratio of 37.95, a P/E/G ratio of 4.68 and a beta of 1.05.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, July 24th. The medical instruments supplier reported $1.84 EPS for the quarter, topping analysts’ consensus estimates of $1.51 by $0.33. West Pharmaceutical Services had a net margin of 16.48% and a return on equity of 18.43%. The firm had revenue of $766.50 million during the quarter, compared to analyst estimates of $725.11 million. During the same quarter in the previous year, the business earned $1.52 EPS. The business’s quarterly revenue was up 9.2% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2025 guidance at 6.650-6.850 EPS. As a group, analysts anticipate that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current year.

West Pharmaceutical Services Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 19th. Stockholders of record on Wednesday, November 12th will be issued a $0.22 dividend. This is a positive change from West Pharmaceutical Services’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend is Wednesday, November 12th. This represents a $0.88 annualized dividend and a dividend yield of 0.3%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 12.57%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on WST shares. UBS Group raised their price objective on shares of West Pharmaceutical Services from $285.00 to $320.00 and gave the stock a “buy” rating in a report on Friday, July 25th. Evercore ISI raised their price objective on shares of West Pharmaceutical Services from $275.00 to $350.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. Wall Street Zen raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. Citigroup reissued a “buy” rating on shares of West Pharmaceutical Services in a report on Thursday, May 22nd. Finally, Barclays assumed coverage on shares of West Pharmaceutical Services in a report on Tuesday, June 24th. They issued an “equal weight” rating and a $245.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $320.71.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.